Stocktoria
BioRestorative Therapies, Inc. BRTX
BioRestorative Therapies, Inc. (BRTX) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $359,700 at a -3959.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BRTX | BioRestorative Therapies, Inc. | 3/9 | — | — | — |
| MGRX | MANGOCEUTICALS, INC. | 2/9 | 2.42 | — | — |
| NIVF | NewGenIvf Group Ltd | 3/9 | 3.84 | 0.6 | — |
| CCEL | CRYO CELL INTERNATIONAL INC | 5/9 | -3.07 | — | -1.3% |
| VMD | VIEMED HEALTHCARE, INC. | 5/9 | 5.41 | 26.5 | +20.5% |
| SHC | Sotera Health Co | 6/9 | — | 63.6 | +5.7% |
| PGNY | Progyny, Inc. | 5/9 | 7.14 | 38.2 | +10.4% |
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.
FAQ
Is BRTX financially healthy?
BioRestorative Therapies, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does BRTX pay a dividend?
No, BioRestorative Therapies, Inc. does not currently pay a dividend.
How profitable is BRTX?
In FY2025, BioRestorative Therapies, Inc. had a net margin of -3959.4% and a return on equity of -3992.2%.
What is the analyst price target for BRTX?
The average Wall-Street price target for BioRestorative Therapies, Inc. is $8.00, about 3668.3% above the recent price, from 2 analysts.
Is BRTX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BioRestorative Therapies, Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.